In today’s rapidly evolving pharmaceutical landscape, biologics manufacturers face intensifying pressure to reduce cost of goods (COGS) while maintaining stringent product quality and accelerating time to market. Intensified Fed-Batch (IFB) has emerged as a leading strategy1. By increasing the N-stage inoculation density through N-1 seed intensification, the production phase is entered rapidly, significantly boosting volumetric productivity without the need for new equipment.
Altruist Biologics has pioneered an innovative IFB platform that addresses these challenges with a comprehensive, technology-driven strategy. By integrating enhanced N-1 seed intensification, tailored proprietary culture media-driven process optimization, the Altruist IFB platform routinely achieves 10% to 85% increases in protein titer, more than 30 intensified projects, and demonstrates consistent scalability up to 20,000 L, supported by representative case studies in both late-stage process changes and early-stage development.
Intensified Fed-Batch vs. Traditional Fed-Batch: Characteristics and Challenges
IFB compresses the production culture timeline by entering the protein expression phase much earlier2. However, high-density cultures impose distinct metabolic demands that must be addressed for success. To address these multifaceted challenges, Altruist Biologics has developed a suite of chemically defined, proprietary basal and feed media specifically engineered for the intensified metabolic environment.
Table 1. Key Features of Traditional Fed-Batch versus Intensified Fed-Batch
| Parameter | Traditional Fed-Batch (TFB) | Intensified Fed-Batch (IFB) |
| Typical inoculation density | (0.5-1.5) × 10⁶ cells/mL | (4.0-6.0) × 10⁶ cells/mL |
| N-1 seed train | Standard passaging | Intensified (fed-batch or perfusion) |
| N-1 stage growth phase duration | 2-4 days | 4-6 days |
| N-stage production phase (% of total) | ~50–65% | Up to ~90% |
| Equipment compatibility | Standard fed-batch | N-1 fed-batch: full compatibility |
| Typical titer range | Baseline | 10–85% potential improvement |
| COGS impact | Baseline | 20–40% reduction potential |
The Altruist IFB Platform: Core Technology Features
N-1 Fed-Batch Seed Intensification – Full Line Compatibility
Unlike perfusion-based approaches, Altruist employs a N-1 fed-batch strategy to achieve high seed density. By extending the N-1 culture duration and incorporating a controlled fed-batch feeding regime, a substantially elevated final viable cell density (VCD) is reached (Figure 1). This method:
- Requires no additional equipment (e.g., no ATF, TFF, or cell retention devices).
- Is directly deployable in any existing fed-batch production line.
- Enables the high-expression, low-temperature production phase to occupy up to ~90% of the N-stage duration, maximizing output per batch.
Figure 1. Schematic of Altruist IFB N-1 Fed-Batch Mode. N-1 seed fed-batch leading to higher viable cell density, N-stage high-density inoculation mode extended production phase.
Proprietary Media Platform
Recognizing that intensified processes impose distinct nutritional demands, Altruist Biologics has developed a proprietary media platform tailored for IFB applications, enabling sustained cellular and metabolic performance through the prolonged, high-productivity expression phase of an intensified batch (Table 2).
Table 2. Altruist Proprietary IFB Media
| Media Attribute | Performance Characteristic |
| Optimized amino acid ratios | Prevents depletion of key amino acids during peak VCD |
| Redox buffer and antioxidant system | Minimizes reactive oxygen species (ROS) accumulation, supporting prolonged viability |
| Lot-to-lot consistency | Tight control of raw material sourcing and blending to ensure robust process performance |
| Cost of goods sold | 50% reduction potential |
Superior Performance and Scalability
Altruist Biologics has successfully developed and executed more than 30 IFB projects spanning laboratory to commercialized scales, with the largest production scale reaching 20,000 L. Across this portfolio, titer increases ranging from 10% to 85% have been achieved relative to the corresponding FB baselines, demonstrating consistent performance in terms of productivity enhancement and scalability. Both GMP and non-GMP runs demonstrate consistent productivity and robust process performance, ensuring reliability across various manufacturing scales (Figure 2).
Figure 2. Titer and scalability summary of the Altruist IFB platform: average titer improvement of 35% across the portfolio, with scale-up titers remaining comparable to those of confirmation batches.
The maturity of the Altruist IFB platform is most clearly demonstrated by the breadth of our project experience. The following table summarizes the distribution of IFB programs across development stages, underscoring that our process has been successfully applied at every point in the biologic’s development lifecycle (Table 3).
Table 3. Altruist IFB Platform – Program Distribution and Maturity Indicators
| Stage | Number of IFB Projects | Representative Achievements |
| IND-enabling / IND filed | >30 | Titer increases of 10–85% |
| Late-stage (Pivotal/PPQ completed) | 5 | 20,000 L, Robust process performance |
| Commercial (Approved) | 1 | 3,000 L, Robust process performance |
| Total IFB batches developed | >40 | Largest scale: 20,000 L |
Representative Case Studies
Case Study 1: Post-approval Process Change from TFB to IFB — 3,000 L and 20,000 L Scale-Up with 50% Titer Improvement
The Altruist team undertook a systematic assessment of the existing FB process and designed an IFB conversion strategy, to meet client required a substantial increase in production capacity to support late-stage clinical supply and future commercial demand. The IFB process achieved a 50% titer increase (7.54 g/L vs. 11.39 g/L), high product purity and consistent 3,000 L and 20,000 L scalability (Figure 3).
Figure 3. Key Performance Comparison: titer increased 50%, large scale titer>10 g/L, with higher purity.
Case Study 2: Late-Stage Process Change from TFB to IFB — 900 L Scale-Up with 70% Titer Improvement
To meet the client’s demand for increased production capacity, Altruist executed a FB-to-IFB process change during clinical stage, increasing small-scale titer from 7.58 g/L to 14.08 g/L and large scale titer from 7.38 g/L to 12.51 g/L (mean), with comparable purity—demonstrating exceptional productivity, product quality, and scalability (Figure 4).
Figure 4. Post-IND FB-to-IFB process change: small-scale titer doubled, large-scale titer reached 12 g/L, with comparable purity.
Conclusion: Enabling a Reliable Strategy for Biologics Manufacturing
The Altruist Biologics IFB platform delivers a practical and powerful route to significantly higher productivity—without requiring additional capital investment in perfusion equipment. By combining N-1 fed-batch seed intensification with proprietary, fit-for-purpose intensified media, the platform routinely provides 10–85% titer enhancement that is predictably scalable to 20,000 L and fully compatible with existing fed-batch facilities. This empowers clients to meet variable clinical and commercial demand with reduced cost of goods, accelerated timelines, and assured product quality—ultimately bringing important biologic therapies to patients faster.
Connect With Us
Speak to our experts about how our platform can dramatically improve cell culture productivity and drive down your biologics manufacturing costs.
References
- Xiang S, et al. Developing an ultra-intensified fed-batch cell culture process with greatly improved performance and productivity. Biotechnol Bioeng. 2024;121(2):526-539.
- Tang, Y., et al. (2024). Fed-batch performance profiles for mAb production using different intensified N-1 seed strategies are CHO cell-line dependent. Biotechnology Progress, 40(4). https://www.ncbi.nlm.nih.gov/m/pubmed/38415506/